Process Related Impurities In Anti-Diabetic Drug Linagliptin

Authors

  • Sukumar Nandi, Akkina Naresh Gona Reddy, Paparaju Venkateswarlu A. Syam Prasad Reddy, K. Shantan Kumar Reddy Chemical Research and Development, Aurobindo Pharma Limited, Andhra Pradesh-502329, India

DOI:

https://doi.org/10.15520/jpro.2015.vol5.iss5.15

Abstract

During the Linagliptin process development, several related substances in the range of 0.05% to 0.15% were observed by high performance liquid chromatography [HPLC] method. Liquid chromatography mass spectrometry [LC-MS] study was performed to identify the molecular mass of these impurities. The origin of these impurities was investigated. These impurities were synthetically prepared and characterized by IR, NMR and Mass analyzes. They were co-injected for their further confirmation. These impurities are 8-[(S)-3-Aminopiperidin-1-yl]-7-(but-2-ynyl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-1H-purine-2,6(3H,7H)-dione (Impurity-I), 7-(But-2-ynyl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-8-(piperidin-3-ylamino)-1H-purine-2,6(3H,7H)-dione (Impurity-II), 8-[(R)-3-Aminopiperidin-1-yl]-3-methyl-1,7-bis((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione (Impurity-III), 8-[(R)-3-Aminopiperidin-1-yl]-1-(but-2-ynyl)-3-methyl-7-[(4-methylquinazolin-2-yl)methyl]-1H-purine-2,6(3H,7H)-dione (Impurity-IV), 1,7-Di(but-2-ynyl)-3-methyl-8-[(R)-3-(methyleneamino) piperidin -1-yl]-1H-purine-2,6(3H,7H)-dione (Impurity-V), 7-(But-2-ynyl)-8-(dimethylamino)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-1H-purine-2,6(3H,7H)-dione (Impurity-VI) and  8-[(R)-3-Aminopiperidin-1-yl]-7-[(E)-3-bromobut-2-enyl]-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-1H-purine-2,6(3H,7H)-dione (Impurity-VII).

Downloads

Published

2015-05-10

How to Cite

A. Syam Prasad Reddy, K. Shantan Kumar Reddy, S. N. A. N. G. R. P. V. (2015). Process Related Impurities In Anti-Diabetic Drug Linagliptin. Journal of Pharmaceutical Research and Opinion, 5(5). https://doi.org/10.15520/jpro.2015.vol5.iss5.15

Issue

Journal of Pharmaceutical Research & Opinion

Section

Articles

License

“I ……………………………………….certify that I have participated sufficiently in the conception and design of this work and the analysis of the data (wherever applicable), as well as the writing of the manuscript, to take public responsibility for it. I believe the manuscript represents valid work. I have reviewed the final version of the manuscript and approve it for publication. Neither has the manuscript nor one with substantially similar content under my authorship been published nor is being considered for publication elsewhere, except as described in an attachment. Furthermore I attest that I shall produce the data upon which the manuscript is based for examination by the editors or their assignees, if requested.”